Great paper to discuss this week - one that may be too good to believe? I highly recommend checking out the pdf first (ebrheum.com/twts) - their graphics are wonderful and do a great job of conveying their message.  Also, check out the "2-5-10" rule that I referenced!  This is required reading for anyone who rotates with me - easily one of the most useful EBM papers I have ever read. 

Quick podcast this week that expands on issues I discuss in Episode 55.  Go back and listen to that one first if you have time!  I think this is an important issue and it's one I'd like to highlight.  Let me know what you think @ebrheum and please share with friends! 

This week I wanted to share a recent systematic review and meta analysis, which was published by myself and a group on behalf of the Global Rheumatology Alliance. I use this as an opportunity to close out a few issues and describe the current landscape.  After this I'm planning to go back to good old rheumatology-based podcasts for a few months! 

The podcast is back!  I tune in briefly here to explain where I've been, what I'm doing, and where this will be headed. Feel free to skip right ahead if you'd rather just dig back in! 

Back this week to update you on the data for hydroxychlorquine.  There has been a lot of action - and very little resolution - to this issue since my last episode.  Let me know what you think, follow along on twitter @ebrheum and get the papers themselves at ebrheum.com.  

Diving into a new "rheum treatments for COVID" topic today - IL6 inhibition. It took me awhile to get to this, in part because the hydroxychloroquine situation has been something to behold and in part because there's just nothing to say. I cover two case series here, neither of which are strong evidence. Hope you enjoy! Follow me @ebrheum to let me know what you think! 

Trying to get to IL6, but so much happening in the world of hydroxychloroquine. As I said at the beginning, things are likely to move fast.  I'm planning to make this as an extended series, so please go back and listen to #1 before you listen to this!  This episode will round out the paper by Gautret et al. and discuss the best copy of a paper by Jun et al. that I've been able to find. Follow me @ebrheum and share with friends! 

Welcome to the first episode of my series on immunosuppressive treatments for COVID-19. Today I cover the Renault trial and a nice systematic review, which I believe are the two best options in the published literature to date.  Find the papers and ways to subscribe at ebrheum.com and follow me on twitter @ebrheum

Quick update podcast.  I'm planning to tweak the format of my podcast to better respond to COVID-19.  I'll be doing more or less the same thing but with a different structure and focus.  It seems a little peculiar to discuss anything else during the current crisis, so I intend to refocus and hope to offer value to listeners.  Share with friends - ebrheum.com and @ebrheum

PEXIVAS has landed!  This week I go over the trial and my take on it's results.  Impressive undertaking that answered two questions for a subset of patients with AAV - well worth the time to kick back and read the trial in full. Let me know what you think about the podcast @ebrheum!